{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:07:31Z","timestamp":1746245251977,"version":"3.40.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01510-1","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T14:39:53Z","timestamp":1739457593000},"page":"214-222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study"],"prefix":"10.1007","volume":"43","author":[{"given":"Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"6","key":"1510_CR1","doi-asserted-by":"publisher","first-page":"5840","DOI":"10.3390\/ijms24065840","volume":"24","author":"D Lavacchi","year":"2023","unstructured":"Lavacchi D, Roviello G, Guidolin A et al (2023) Evaluation of fruquintinib in the continuum of care of patients with colorectal cancer. Int J Mol Sci 24(6):5840. https:\/\/doi.org\/10.3390\/ijms24065840","journal-title":"Int J Mol Sci"},{"key":"1510_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jgo.2017.08.001","volume":"9","author":"A Gouverneur","year":"2018","unstructured":"Gouverneur A, Salvo F, Berda\u00ef D et al (2018) Inclusion of elderly or frail patients in randomized controlled trials of targeted therapies for the treatment of metastatic colorectal cancer: a systematic review. J Geriatr Oncol 9:15\u201323. https:\/\/doi.org\/10.1016\/j.jgo.2017.08.001","journal-title":"J Geriatr Oncol"},{"key":"1510_CR3","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1038\/s41416-022-01737-2","volume":"126","author":"E Van Cutsem","year":"2022","unstructured":"Van Cutsem E, Danielewicz I, Saunders MP et al (2022) First-line trifluridine\/tipiracil+bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study. Br J Cancer 126:1548\u20131554. https:\/\/doi.org\/10.1038\/s41416-022-01737-2","journal-title":"Br J Cancer"},{"key":"1510_CR4","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1200\/jco.2008.20.2879","volume":"27","author":"DJ Sargent","year":"2009","unstructured":"Sargent DJ, K\u00f6hne CH, Sanoff HK et al (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 27:1948\u20131955. https:\/\/doi.org\/10.1200\/jco.2008.20.2879","journal-title":"J Clin Oncol"},{"issue":"9","key":"1510_CR5","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3390\/medicina59091574","volume":"59","author":"IA Voutsadakis","year":"2023","unstructured":"Voutsadakis IA (2023) Presentation, molecular characteristics, treatment, and outcomes of colorectal cancer in patients older than 80 years old. Medicina (Kaunas) 59(9):1574. https:\/\/doi.org\/10.3390\/medicina59091574","journal-title":"Medicina (Kaunas)"},{"key":"1510_CR6","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/s1470-2045(13)70154-2","volume":"14","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Lang I, Marcuello E et al (2013) Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 14:1077\u20131085. https:\/\/doi.org\/10.1016\/s1470-2045(13)70154-2","journal-title":"Lancet Oncol"},{"key":"1510_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/annonc\/mdx529","volume":"29","author":"T Aparicio","year":"2018","unstructured":"Aparicio T, Bouch\u00e9 O, Taieb J et al (2018) Bevacizumab + chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial-PRODIGE 20 study results. Ann Oncol 29:133\u2013138. https:\/\/doi.org\/10.1093\/annonc\/mdx529","journal-title":"Ann Oncol"},{"key":"1510_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2468-1253(22)00334-X","volume":"8","author":"T Andre","year":"2023","unstructured":"Andre T, Falcone A, Shparyk Y et al (2023) Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. Lancet Gastroenterol Hepatol 8:133\u2013144. https:\/\/doi.org\/10.1016\/S2468-1253(22)00334-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1510_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/14656566.2024.2336069","volume":"25","author":"E Stucchi","year":"2024","unstructured":"Stucchi E, Bartolini M, Airoldi M et al (2024) Fruquintinib as new treatment option in metastatic colorectal cancer patients: is there an optimal sequence? Expert Opin Pharmacother 25:371\u2013382. https:\/\/doi.org\/10.1080\/14656566.2024.2336069","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1510_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/jcm13010057","volume":"13","author":"J Zou","year":"2023","unstructured":"Zou J, Wang Y, Xu J et al (2023) A retrospective study of trifluridine\/tipiracil with fruquintinib in patients with chemorefractory metastatic colorectal cancer. J Clin Med 13(1):57. https:\/\/doi.org\/10.3390\/jcm13010057","journal-title":"J Clin Med"},{"key":"1510_CR11","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1007\/s12325-020-01477-w","volume":"37","author":"J Li","year":"2020","unstructured":"Li J, Guo W, Bai Y et al (2020) Safety profile and adverse events of special interest for fruquintinib in Chinese patients with previously treated metastatic colorectal cancer: analysis of the phase 3 FRESCO trial. Adv Ther 37:4585\u20134598. https:\/\/doi.org\/10.1007\/s12325-020-01477-w","journal-title":"Adv Ther"},{"issue":"20","key":"1510_CR12","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.3390\/jcm13206193","volume":"13","author":"AA Samara","year":"2024","unstructured":"Samara AA, Diamantis A, Magouliotis D et al (2024) Assessing preoperative (EORTC) QLQ-C30 score in elderly patients with colorectal cancer: results from a prospective cohort study. J Clin Med 13(20):6193. https:\/\/doi.org\/10.3390\/jcm13206193","journal-title":"J Clin Med"},{"key":"1510_CR13","doi-asserted-by":"publisher","first-page":"8398","DOI":"10.1002\/14651858.CD008398.pub2","volume":"7","author":"F Chionh","year":"2017","unstructured":"Chionh F, Lau D, Yeung Y et al (2017) Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 7:8398. https:\/\/doi.org\/10.1002\/14651858.CD008398.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1510_CR14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R et al (2023) Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 402:41\u201353. https:\/\/doi.org\/10.1016\/s0140-6736(23)00772-9","journal-title":"Lancet"},{"key":"1510_CR15","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.2018.7855","volume":"319","author":"J Li","year":"2018","unstructured":"Li J, Qin S, Xu RH et al (2018) Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA 319:2486\u20132496. https:\/\/doi.org\/10.1001\/jama.2018.7855","journal-title":"JAMA"},{"key":"1510_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3892\/ol.2022.13261","volume":"23","author":"X Chu","year":"2022","unstructured":"Chu X, Xue P, Zhu S (2022) Management of chemotherapy dose intensity for metastatic colorectal cancer. Oncol Lett 23:141. https:\/\/doi.org\/10.3892\/ol.2022.13261","journal-title":"Oncol Lett"},{"key":"1510_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-016-0384-9","volume":"10","author":"RH Xu","year":"2017","unstructured":"Xu RH, Li J, Bai Y et al (2017) Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol 10:22. https:\/\/doi.org\/10.1186\/s13045-016-0384-9","journal-title":"J Hematol Oncol"},{"key":"1510_CR18","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.eclinm.2023.102315","volume":"66","author":"W Zhao","year":"2023","unstructured":"Zhao W, Lei J, Ke S et al (2023) Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). EClinicalMedicine 66:102315. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102315","journal-title":"EClinicalMedicine"},{"key":"1510_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/13696998.2021.1888743","volume":"24","author":"X Guan","year":"2021","unstructured":"Guan X, Li H, Xiong X et al (2021) Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China. J Med Econ 24:339\u2013344. https:\/\/doi.org\/10.1080\/13696998.2021.1888743","journal-title":"J Med Econ"},{"key":"1510_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/cam4.3618","volume":"10","author":"E Oki","year":"2021","unstructured":"Oki E, Makiyama A, Miyamoto Y et al (2021) Trifluridine\/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): a multicenter phase II trial. Cancer Med 10:454\u201361. https:\/\/doi.org\/10.1002\/cam4.3618","journal-title":"Cancer Med"},{"key":"1510_CR21","doi-asserted-by":"publisher","first-page":"102202","DOI":"10.1016\/j.ctrv.2021.102202","volume":"97","author":"L Salvatore","year":"2021","unstructured":"Salvatore L, Bria E, Sperduti I et al (2021) Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: a meta-analysis of individual patients\u2019 data from 3 phase III studies. Cancer Treat Rev 97:102202. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102202","journal-title":"Cancer Treat Rev"},{"key":"1510_CR22","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13063-020-4194-6","volume":"21","author":"M Shi","year":"2020","unstructured":"Shi M, Ma T, Xi W et al (2020) A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer. Trials 21:249. https:\/\/doi.org\/10.1186\/s13063-020-4194-6","journal-title":"Trials"},{"key":"1510_CR23","doi-asserted-by":"publisher","first-page":"e240084","DOI":"10.57264\/cer-2024-0084","volume":"13","author":"VF Paly","year":"2024","unstructured":"Paly VF, Dasari A, Hubbard J et al (2024) Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapy and biologics in the US. J Comp Eff Res 13:e240084. https:\/\/doi.org\/10.57264\/cer-2024-0084","journal-title":"J Comp Eff Res"},{"key":"1510_CR24","doi-asserted-by":"publisher","first-page":"719836","DOI":"10.3389\/fonc.2021.719836","volume":"11","author":"T Yang","year":"2021","unstructured":"Yang T, Xiao H, Liu X et al (2021) Vascular normalization: a new window opened for cancer therapies. Front Oncol 11:719836. https:\/\/doi.org\/10.3389\/fonc.2021.719836","journal-title":"Front Oncol"},{"key":"1510_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12916-022-02357-6","volume":"20","author":"Y Liu","year":"2022","unstructured":"Liu Y, Xiao Q, He J et al (2022) Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS\/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy. BMC Med 20:155. https:\/\/doi.org\/10.1186\/s12916-022-02357-6","journal-title":"BMC Med"},{"issue":"8","key":"1510_CR26","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/cancers16081460","volume":"16","author":"B P\u00e9csi","year":"2024","unstructured":"P\u00e9csi B, Mangel LC (2024) The real-life impact of primary tumor resection of synchronous metastatic colorectal cancer-from a clinical oncologic point of view. Cancers (Basel) 16(8):1460. https:\/\/doi.org\/10.3390\/cancers16081460","journal-title":"Cancers (Basel)"},{"key":"1510_CR27","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.2147\/OTT.S307273","volume":"14","author":"S Qin","year":"2021","unstructured":"Qin S, Xu RH, Shen L et al (2021) Subgroup analysis by liver metastasis in the FRESCO trial comparing fruquintinib versus placebo plus best supportive care in Chinese patients with metastatic colorectal cancer. Onco Targets Ther 14:4439\u20134450. https:\/\/doi.org\/10.2147\/OTT.S307273","journal-title":"Onco Targets Ther"},{"key":"1510_CR28","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40266-021-00869-z","volume":"38","author":"E Correa","year":"2021","unstructured":"Correa E, Lindsay T, Dotan E (2021) Management of metastatic colorectal carcinoma in older adults: balancing risks and benefits of novel therapies. Drugs Aging 38:639\u2013654. https:\/\/doi.org\/10.1007\/s40266-021-00869-z","journal-title":"Drugs Aging"},{"key":"1510_CR29","doi-asserted-by":"publisher","first-page":"e1012","DOI":"10.1093\/oncolo\/oyae073","volume":"29","author":"J Li","year":"2024","unstructured":"Li J, Wang Z, Zhong H et al (2024) A phase IV study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice. Oncologist 29:e1012\u2013e9. https:\/\/doi.org\/10.1093\/oncolo\/oyae073","journal-title":"Oncologist"},{"key":"1510_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.21037\/tcr-22-1872","volume":"12","author":"YY Deng","year":"2023","unstructured":"Deng YY, Chen YW, Wang MX et al (2023) Acute aortic dissection caused by fruquintinib for metastatic colorectal cancer-a case report and literature review. Transl Cancer Res 12:177\u201385. https:\/\/doi.org\/10.21037\/tcr-22-1872","journal-title":"Transl Cancer Res"},{"key":"1510_CR31","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.heares.2006.02.004","volume":"214","author":"PM Picciotti","year":"2006","unstructured":"Picciotti PM, Fetoni AR, Paludetti G et al (2006) Vascular endothelial growth factor (VEGF) expression in noise-induced hearing loss. Hear Res 214:76\u201383. https:\/\/doi.org\/10.1016\/j.heares.2006.02.004","journal-title":"Hear Res"},{"key":"1510_CR32","doi-asserted-by":"publisher","first-page":"e34210","DOI":"10.1097\/MD.0000000000034210","volume":"102","author":"Y Qi","year":"2023","unstructured":"Qi Y, Cui L, Zhang L et al (2023) Effect of repeated intravitreal anti-vascular endothelial growth factor drugs on corneal nerves. Medicine (Baltimore) 102:e34210. https:\/\/doi.org\/10.1097\/MD.0000000000034210","journal-title":"Medicine (Baltimore)"},{"key":"1510_CR33","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s10637-009-9314-9","volume":"28","author":"DM Hartl","year":"2010","unstructured":"Hartl DM, Ferte C, Loriot Y et al (2010) Dysphonia induced b-y vascular endothelium growth factor\/vascular endothelium growth factor receptor inhibitors. Invest New Drugs 28:884\u2013886. https:\/\/doi.org\/10.1007\/s10637-009-9314-9","journal-title":"Invest New Drugs"},{"issue":"6","key":"1510_CR34","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.3390\/cancers14061410","volume":"14","author":"LJ Palmieri","year":"2022","unstructured":"Palmieri LJ, Buchler T, Meyer A et al (2022) Impact of delaying the addition of anti-EGFR in first line of RAS wild-type metastatic colorectal cancer: a propensity-weighted pooled data analysis. Cancers (Basel) 14(6):1410. https:\/\/doi.org\/10.3390\/cancers14061410","journal-title":"Cancers (Basel)"},{"key":"1510_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12885-019-5","volume":"19","author":"A Carrato","year":"2019","unstructured":"Carrato A, Benavides M, Massuti B et al (2019) First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC Cancer 19:533. https:\/\/doi.org\/10.1186\/s12885-019-5","journal-title":"BMC Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01510-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01510-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:39:54Z","timestamp":1746193194000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01510-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1510"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01510-1","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study procedures were approved by the Ethics Committee of Beijing Friendship Hospital and conducted in accordance with the Declaration of Helsinki and ethical guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The clinical data of each patient were complete and true, and written informed consents were obtained from the patients and their children.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}